Equities analysts expect Entellus Medical Inc (NASDAQ:ENTL) to announce $28.75 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Entellus Medical’s earnings. The lowest sales estimate is $28.50 million and the highest is $28.99 million. Entellus Medical reported sales of $21.67 million in the same quarter last year, which indicates a positive year-over-year growth rate of 32.7%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, February 20th.

According to Zacks, analysts expect that Entellus Medical will report full year sales of $28.75 million for the current fiscal year, with estimates ranging from $93.00 million to $93.56 million. For the next year, analysts forecast that the company will report sales of $118.77 million per share, with estimates ranging from $114.60 million to $123.50 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Entellus Medical.

Entellus Medical (NASDAQ:ENTL) last issued its quarterly earnings data on Wednesday, November 1st. The medical technology company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.02. Entellus Medical had a negative return on equity of 47.37% and a negative net margin of 31.24%.

ENTL has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Entellus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, October 31st. BidaskClub lowered Entellus Medical from a “sell” rating to a “strong sell” rating in a research report on Tuesday. TheStreet upgraded Entellus Medical from a “d” rating to a “c-” rating in a research report on Thursday, December 14th. William Blair lowered Entellus Medical from an “outperform” rating to a “market perform” rating in a research report on Friday, December 8th. Finally, ValuEngine upgraded Entellus Medical from a “sell” rating to a “hold” rating in a research report on Thursday, December 7th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $19.25.

Shares of Entellus Medical (NASDAQ:ENTL) traded down $0.02 during mid-day trading on Friday, hitting $24.04. The stock had a trading volume of 56,211 shares, compared to its average volume of 156,767. The company has a market cap of $617.09, a price-to-earnings ratio of -18.64 and a beta of 0.02. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $25.58. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32.

In other Entellus Medical news, insider Robert S. White sold 3,471 shares of Entellus Medical stock in a transaction on Friday, January 5th. The stock was sold at an average price of $24.01, for a total transaction of $83,338.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Thomas P. Williamson sold 2,449 shares of Entellus Medical stock in a transaction on Monday, January 8th. The shares were sold at an average price of $24.08, for a total value of $58,971.92. The disclosure for this sale can be found here. Insiders have sold 108,942 shares of company stock worth $2,599,658 over the last 90 days. 7.70% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the business. Nationwide Fund Advisors raised its stake in Entellus Medical by 61.7% during the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after buying an additional 2,635 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Entellus Medical by 145.1% during the third quarter. JPMorgan Chase & Co. now owns 9,469 shares of the medical technology company’s stock valued at $168,000 after buying an additional 5,605 shares during the last quarter. Wells Fargo & Company MN raised its stake in Entellus Medical by 74.7% during the third quarter. Wells Fargo & Company MN now owns 11,329 shares of the medical technology company’s stock valued at $209,000 after buying an additional 4,846 shares during the last quarter. Kopp Investment Advisors LLC raised its stake in Entellus Medical by 0.5% during the second quarter. Kopp Investment Advisors LLC now owns 11,874 shares of the medical technology company’s stock valued at $197,000 after buying an additional 55 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Entellus Medical by 61.7% during the second quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock valued at $196,000 after buying an additional 4,533 shares during the last quarter. Institutional investors and hedge funds own 78.24% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/20/entellus-medical-inc-entl-expected-to-post-quarterly-sales-of-28-75-million.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Get a free copy of the Zacks research report on Entellus Medical (ENTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.